Apollon Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
Other funds holding REGN
Apollon Wealth Management's REGN Position: Q2 2026 in Review
Apollon Wealth Management increased its Regeneron Pharmaceuticals (REGN) stake by 74% in Q2 2026, buying an estimated $1.93M and bringing the position to 6,662 shares worth $4.15M. The position accounts for 0.05% of the portfolio, ranked #303.
Apollon Wealth Management first reported a position in REGN in Q2 2020 and has held it in 23 quarters since. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Apollon Wealth Management held 6,662 shares of Regeneron Pharmaceuticals worth $4.15M as of Q2 2026.
- Apollon Wealth Management bought 2,831 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $1.93M.
- Regeneron Pharmaceuticals made up 0.05% of Apollon Wealth Management's portfolio in Q2 2026, its #303 holding.
- Apollon Wealth Management first reported a position in Regeneron Pharmaceuticals in Q2 2020 and has held it in 23 quarters since.
- 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Apollon Wealth Management's 13F filing for Q2 2026, filed 23 Jul 2026.